198 related articles for article (PubMed ID: 25006983)
1. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Kuhnert M; Steuber H; Diederich WE
J Med Chem; 2014 Jul; 57(14):6266-72. PubMed ID: 25006983
[TBL] [Abstract][Full Text] [Related]
2. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
Dostál J; Brynda J; Hrušková-Heidingsfeldová O; Pachl P; Pichová I; Rezáčová P
J Enzyme Inhib Med Chem; 2012 Feb; 27(1):160-5. PubMed ID: 22146051
[TBL] [Abstract][Full Text] [Related]
3. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
Kuhnert M; Blum A; Steuber H; Diederich WE
J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
[TBL] [Abstract][Full Text] [Related]
4. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies and comparative analysis on structurally similar HTLV and HIV protease using HIV-PR inhibitors.
Selvaraj C; Singh P; Singh SK
J Recept Signal Transduct Res; 2014 Oct; 34(5):361-71. PubMed ID: 24694004
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod M; Borg-von Zepelin M; Telenti A; Sanglard D
Dermatology; 1999; 198(4):412-4. PubMed ID: 10490300
[No Abstract] [Full Text] [Related]
7. Reconstruction of the binding pathway of an anti-HIV drug, Indinavir, in complex with the HTLV-1 protease using unaggregated unbiased molecular dynamics simulation.
Sohraby F; Aryapour H
Comput Biol Chem; 2022 Feb; 96():107616. PubMed ID: 34883394
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by supervised molecular dynamics simulation.
Sohraby F; Aryapour H
PLoS One; 2021; 16(9):e0257916. PubMed ID: 34570822
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro.
Gruber A; Speth C; Lukasser-Vogl E; Zangerle R; Borg-von Zepelin M; Dierich MP; Würzner R
Immunopharmacology; 1999 Apr; 41(3):227-34. PubMed ID: 10428651
[TBL] [Abstract][Full Text] [Related]
11. HIV protease inhibitors.
Carr A; Cooper DA
AIDS; 1996; 10 Suppl A():S151-7. PubMed ID: 8883623
[No Abstract] [Full Text] [Related]
12. Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.
Selvaraj C; Omer A; Singh P; Singh SK
Mol Biosyst; 2015 Jan; 11(1):178-89. PubMed ID: 25335799
[TBL] [Abstract][Full Text] [Related]
13. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
14. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases.
Bagossi P; Kádas J; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol Methods; 2004 Aug; 119(2):87-93. PubMed ID: 15158589
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
[TBL] [Abstract][Full Text] [Related]
16. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
17. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
King NM; Melnick L; Prabu-Jeyabalan M; Nalivaika EA; Yang SS; Gao Y; Nie X; Zepp C; Heefner DL; Schiffer CA
Protein Sci; 2002 Feb; 11(2):418-29. PubMed ID: 11790852
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design.
Wlodawer A; Vondrasek J
Annu Rev Biophys Biomol Struct; 1998; 27():249-84. PubMed ID: 9646869
[TBL] [Abstract][Full Text] [Related]
19. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.
Selvaraj C; Singh P; Singh SK
J Mol Recognit; 2014 Dec; 27(12):696-706. PubMed ID: 25319617
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
